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Abstract
Mutations in the ATP-binding cassette transporter 1 (ABCA1) gene have been recently identified as the molecular defect in
Tangier disease (TD) and familial high density lipoprotein deficiency (FHA). We here report novel mutations in the ABCA1
gene in two sisters from a Japanese family with TD who have been described previously (S. Ohtaki, H. Nakagawa, N. Kida,
H. Nakamura, K. Tsuda, S. Yokoyama, T. Yamamura, S. Tajima, A. Yamamoto, Atherosclerosis 49 (1983)) and a family
with FHA. Both probands of TD and FHA developed coronary heart disease. Sequence analysis of the ABCA1 gene from
the patients with TD revealed a homozygous G to A transition at nucleotide 3805 of the cDNA resulting in the substitution
of Asp 1229 with Asn in exon 27, and a C to T at nucleotide 6181 resulting in the substitution of Arg 2021 with Trp in exon
47. Sequence analysis of the ABCA1 gene from the FHA patient revealed a homozygous 4 bp CGCC deletion from
nucleotide 3787 to 3790 resulting in premature termination by frameshift at codon 1224. These mutations were confirmed by
restriction digestion analysis, and were not found in 141 control subjects. Our findings indicate that mutations in the ABCA1
gene are associated with TD as well as FHA. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Tangier disease (TD) is an inherited condition
characterized by almost complete absence of high
density lipoprotein (HDL) cholesterol and by the ac-
cumulation of cholesteryl ester in various tissues, in-
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cluding tonsils, liver, spleen, intestines, and Schwann
cells [1]. The reduced HDL is inherited in an auto-
somal co-dominant mode, with heterozygotes show-
ing approximately half normal HDL undiscernible
from other cases of familial HDL de¢ciency (FHA)
[1]. On the other hand, FHA has been described in
patients with a markedly decreased plasma HDL
cholesterol (less than ¢fth percentile), and reduced
apolipoprotein (apo) A-I level, but absence of
LCAT or apoA-I gene defect or clinical manifesta-
tion of TD [2,3]. Patients with TD show a moderate
reduction in low density lipoprotein (LDL) and high
levels of triglycerides. Fibroblasts from patients with
TD are defective in apolipoprotein-mediated e¥ux of
both cholesterol and phospholipid, suggesting that
the markedly decreased HDL level in TD may result
from failure of nascent apoA-I to acquire lipids from
cells [4^7]. It has been recently demonstrated that
cellular cholesterol e¥ux is also abnormal in some
patients with FHA [8].
The genetic defect in TD has recently been con-
¢ned to chromosome 9q31 using a graphical linkage
analysis by Rust et al. [9]. One of the genes that had
been previously broadly mapped to the respective
region was ABC1 [10]. Further narrowing and anal-
ysis of the human candidate region demonstrated
human ABC1 within the narrowed candidate region
[11]. Subsequent studies have demonstrated that mu-
tations in the ABCA1 gene are the underlying defect
in TD [3,11,12], and are also found in patients with
FHA, the genetic mutation of which was also local-
ized in the same region (9q31) as TD [3]. The
ABCA1 is a member of the superfamily of ATP
binding cassette (ABC) transporters involved in
membrane transport of diverse substrates including
amino acids, peptides, vitamins, and steroid hor-
mones [13]. The full-size ABC proteins are character-
ized by two nucleotide binding folds (NBF) with
conserved Walker A and B motifs and two trans-
membrane domains, each consisting of six mem-
brane-spanning helicals [10].
Mutations in speci¢c ABC transporters have been
reported as the underlying defects of several human
diseases. For example, cystic ¢brosis is caused by
mutations of the cystic ¢brosis transmembrane con-
ductance regulator gene [14]. Recently, the human
ABCA1 gene has been cloned and shown to play
an important role in lipid transport of macrophages
[15]. In the present study, we isolated and cultivated
monocyte-derived macrophages from Japanese pa-
tients with TD and FHA, and identi¢ed three muta-
tions in the ABCA1 gene in these patients.
2. Materials and methods
2.1. Description of patients
Two siblings with marked reduction of plasma
HDL were previously identi¢ed in a Japanese family
(Fig. 1A, II-3 and II-4) [16]. The serum concentra-
tion of HDL cholesterol in the proband (Fig. 1A, II-
4) was 2.7 mg/dl, and the concentrations of apoA-I
and apoA-II were almost undetectable in the serum.
In addition, the concentrations of LDL cholesterol
and triglycerides in plasma were 30 mg/dl and 83 mg/
dl, respectively. Hepatosplenomegaly was noted in
both siblings; lipid deposition was noted in reticu-
loendothelial cells on liver biopsy of the proband.
The proband was free from ischemic heart disease
at the age of 29 years when she was diagnosed
with TD. However, she developed typical e¡ort an-
Fig. 1. (A) Pedigree of the TD family. (B) Pedigree of the FHD family. Squares, males; circles, females. A¡ected individuals are
marked by solid symbols and heterozygous family members by half-solid symbols. Arrow indicates the proband.
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gina at the age of 37 years and was diagnosed with a
single vessel disease at the age of 44 years. She also
had mitral regurgitation (grade III), ventricular pre-
mature contraction, impaired glucose tolerance and
manic depression illness. Her elder sister (Fig. 1A, II-
3) also had manic depression illness but no signs of
ischemic heart disease. Further details of the clinical
features and biochemical data of these two patients
have been described previously [16].
The proband with HDL de¢ciency (Fig. 1B, II-2)
was a 62 year old Japanese man who presented at
age 45 years at the Amami Central Hospital with
bronchial asthma. He began to notice chest oppres-
sion at age 50 and entered the hospital for treatment
at age 53. He was 154 cm tall and weighed 55 kg.
Physical examination on admission revealed hyper-
tension (168/80 mmHg) and anemia. There was no
tonsillar abnormality, lymphadenopathy, hepatosple-
nomegaly, or xanthomas, and no evidence of neuro-
pathy. Laboratory tests showed normocytic anemia
(hemoglobin: 8.9 g/dl) and hypolipoproteinemia (to-
tal cholesterol 55 mg/dl, triglyceride 42 mg/dl, HDL
cholesterol 7 mg/dl; these values were measured at
age 45 years, see [16] for details). The electrophoretic
separation of serum lipoproteins on agarose gel re-
vealed no de¢nite K band. There were no sings of
diabetes mellitus, thyroid dysfunction, or renal dis-
ease. Coronary angiography revealed 99% stenosis
on the left coronary artery and required percutane-
ous transcutaneous coronary angioplasty. Plasma
and lipoprotein lipid levels of the proband and his
family members are shown in Table 1. HDL choles-
terol and apoA-I levels of his mother, three daugh-
ters and son were 27 and 30% lower than those of
control subjects. All patients gave informed consent
prior to participation in this study.
2.2. Cell culture
Peripheral blood monocytes were isolated using
Lymphoprep Separation Solution (Nycomed Phar-
ma, Norway), then suspended in RPMI 1640 me-
dium supplemented with 10% human type AB serum
(Sigma, St. Louis, MO, USA), penicillin and strepto-
mycin. Monocytes were plated in 10 cm culture
dishes (Falcon Labware) and incubated for 1^3 h
at 37‡C. Non-adherent cells were subsequently re-
moved by washing the dishes with PBS, and the re-
maining adherent cells were grown in culture me-
dium for 2 weeks, with replacement of the medium
every 3 days.
2.3. Reverse transcription (RT)-PCR ampli¢cation
and sequence analysis
Total cellular RNA was isolated from monocyte-
derived macrophages using a commercially available
kit (Isogen, Wako Pure Chemical Industries, Japan).
In the next step, 1 Wg RNA was reverse transcribed
using the Ready-To-Go T-primed ¢rst-strand kit
(Amersham Pharmacia Biotech). An aliquot of the
cDNA was ampli¢ed by AmpliTaq DNA polymerase
(Perkin-Elmer, Norwalk, CT, USA). The primers for
ampli¢ed human ABCA1 cDNA were exactly similar
Table 1
Lipoprotein pro¢les of subjects from a Japanese family with familial HDL de¢ciency
Subject Age
(years)
Sex ABCA1 4 bp
deletion
Cholesterol (mg/dl) Triglyceride
(mg/dl)
Apolipoprotein (mg/dl)
Total Total HDL A-I A-II B E
I 2 82 F +/3 122 37 78 101 22 65 3
II 1a 62 M +/+ 66 3.5 69 6 2 27 1.5
III 1 36 F +/3 150 47 58 112 21 66 4.2
2 34 M +/3 184 39 100 89 27 86 6.2
3 24 F +/3 116 40 62 11 20 53 3.9
4 21 F +/3 149 51 139 117 25 78 2.9
Normal controlsb
Males (n = 15) 192 þ 27 52 þ 18 118 þ 32 146 þ 20 32 þ 5 102 þ 24 4.2 þ 1.1
Females(n = 16) 195 þ 26 58 þ 20 108 þ 40 154 þ 22 34 þ 6 98 þ 25 4.1 þ 1.0
aProband.
bMean þ S.D.
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to those described previously [15]. All PCR products
were subcloned into the pT7Blue-T vector (Novagen)
after puri¢cation with a GeneClean kit (Bio101).
Twelve clones of both strands in opposite directions
of each subcloned fragment were sequenced using a
DNA sequencing kit (Dye terminator cycle sequenc-
ing ready reaction, Perkin-Elmer) with an ABI 373
DNA sequencer according to the protocol recom-
mended by the manufacturer. In addition, exons 27
and 47 of ABCA1 from genomic DNA of two sib-
lings were also sequenced to con¢rm the identi¢ed
mutations. The ABCA1 gene sequence is based on
a published sequence in GenBank, accession No.
AJ012376. The numbering of the exon is based on
newly published data [17]. Sequence analyses of
apoA-I and LCAT genes of the proband of FHA
were performed as described previously [18^20].
2.4. Restriction fragment length polymorphism
analysis (RFLP)
Genomic DNA was isolated from peripheral blood
as described previously [18]. Genotyping for the TD
patient was performed by PCR ampli¢cation of exon
27 followed by restriction digestion with TspEI for
G3805A, and ampli¢cation of exon 47 followed by
digestion with AgeI for C6181T, respectively. The
primers for exon 27 were: (forward) 5P-TTGT-
GCCTTCAGATGGTACCTTGC-3P, (reverse) 5P-
TCAGAATCATTTGGATCAGCAGAAT-3P ; the
primers for exon 47 were: (forward) 5P-CACAGG-
CATGGATCCCAAAGACCG-3P, (reverse) 5P-CTA-
CGGACCTATGAGATGTAAGCAC-3P. Genotyp-
ing was performed by PCR ampli¢cation of exon 7
followed by restriction digestion with Eco81I for
G596A, and ampli¢cation of exon 27 followed by
digestion with NspV for the CGCC3787-3790 dele-
tion, respectively. The primers for exon 7 were: (for-
ward) 5P-GTTTCTGAGCTTTGTGGCCTACCTA-
3P, (reverse) 5P-CTACTCACCAGGATTGGCTTC-
AGG-3P ; the primers for exon 27 were: (forward)
5P-TTGTGCCTTCAGATGGTACCTTGC-3P, (re-
verse) 5P-TCAGCAGCATCATCTTCAGTGTTCG-
3P. The underlined bases indicate mutagenized nu-
cleotides so that the restriction cutting sites for
TspEI, AgeI, Eco81I, and NspV are generated in
the case of G3805A, C6181T, G596A, and the
CGCC3787-3790 deletion, respectively. The nucleo-
tide sequence for the human ABCA1 gene and the
intron^exon boundaries of the ABCA1 gene are
based on published data [3,15,21]. A total of 141
healthy Japanese individuals were recruited as con-
trol subjects. Control subjects gave informed consent
prior to participation in this study.
2.5. Plasma lipoprotein characterization
Blood samples were collected in Na2 EDTA after a
12 h fast. Lipoproteins were isolated by sequential
ultracentrifugation. The following density fractions
were obtained: very low density lipoprotein
(VLDL) (d6 1.019 g/ml), LDL (1.019^1.063 g/ml)
and HDL (1.063^1.21 g/ml) [18]. Plasma cholesterol
and triglyceride values were determined by enzymatic
methods [18]. HDL cholesterol was quantitated by
the heparin-manganese precipitation method [18].
Apolipoproteins were measured by the single radial
immunodi¡usion method [18].
3. Results and discussion
In the present study, we isolated and cultivated
monocyte-derived macrophages from one of two pre-
viously described siblings with Tangier disease [16].
Nine overlapping PCR fragments spanning the whole
ABCA1 cDNA coding the mature product were am-
pli¢ed by RT-PCR, as described in Section 2. Both
strands were sequenced throughout. It should be
noted that we used the primers by Langmann et al.
[15] to sequence cDNA of the ABC1 gene that en-
code the mature product of the ABC1 gene, and
cover exon 2 to exon 50 based on updated sequence
information [17]; thus our sequencing did not in-
clude the updated sequence (exon 1) coding 60 amino
acids. Two novel homozygous missense mutations
were identi¢ed, at nucleotide 3805 with a G to A
transition, and at nucleotide 6181 with a C to T
transition, in cDNA from the sister of the proband
(Fig. 2). The two mutations resulted in the substitu-
tion of Asp 1229 with Asn in exon 27, and substitu-
tion of Arg 2021 with Trp in exon 47, respectively.
Both mutations were also con¢rmed by sequencing
exons 27 and 47 of ABCA1 from genomic DNA of
the two siblings (data not shown). RFLP analysis of
genomic DNA from the two siblings further con-
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¢rmed the mutations (Fig. 2). Sequence analysis of
the ABCA1 gene from the HDL de¢ciency patient
revealed a homozygous 4 bp deletion at nucleotides
3787^3790 of the cDNA in exon 27, resulting in pre-
mature termination by frameshift at codon 1224
(Fig. 3). RFLP analysis of genomic DNA from the
proband further con¢rmed the mutation (Fig. 3).
The mother, three daughters and a son of the pro-
band of FHA were found to be heterozygous for the
4 bp mutation (data not shown). In addition, we
found a G596A mutation in exon 7, but this muta-
tion was also detected in some of the control sub-
jects. These three mutations were not found in 141
normal subjects with RFLP, indicating that they are
not polymorphisms. However, the G596A mutation
was considered to be a polymorphism, since we
found 29 homozygous and 21 heterozygous in 141
normal control subjects. In addition, the sequences
determined in the patient and one control subject
di¡ered in eight nucleotides in the 6603 bp open
reading frame from that registered in GenBank (ac-
cession No. AJ012376) [15]. They were C for T at
nucleotide 705, C for A at 1980, G for A at 3805, C
for T at 4604, C for T 4883, G for T at 5861, C for T
at 6181, and C for T at 6443. All these eight nucleo-
tides were found in both the patient and the normal
subject, and are consistent with data reported previ-
ously [22].
To our knowledge, 22 mutations in ABCA1 have
so far been reported in 19 families with TD. Muta-
tions in TD are distributed throughout the ABCA1
encoded protein, and many of them are clustered
close to the ATP-binding cassette domain. The mu-
tation at amino acid 1229 is close to the ¢rst ATP-
binding cassette domain, and the mutation at amino
acid 2021 is located within the second ATP-binding
cassette domain. Furthermore, amino acids 1229 and
2021 are conserved between human and mouse
ABCA1 and in a Caenorhabditis elegans homologue,
indicating that these two amino acids are probably of
functional importance. At present, however, which of
the two mutations is mainly associated with the TD
phenotype could not be determined in our case. Ini-
tially, we thought that one of these mutations would
be a polymorphism, but we screened 141 normal
subjects, and none of them was found to have such
a mutation. Recently, four novel ABCA1 mutations
in unrelated TD kindreds have been reported by
Brousseau et al. [23], and one of these, from Japa-
nese TD kindreds (TD 18-1, TD 18-2), was identical
to ours. We also con¢rmed that the TD siblings re-
ported by Brousseau et al. were identical to ours.
However, these investigators did not mention the
Fig. 2. Sequence analysis of the ABCA1 gene in a sister of the
proband with Tangier disease. (A) cDNA sequences of a
healthy control subject and a sister of the proband (Fig. 1, II-
3) are shown for part of exon 27 of the ABCA1 gene. Arrow
indicates the G to A transition at nucleotide 3805. The patient
is homozygous for the mutation. (Bottom) Restriction digestion
polymorphism analysis of patients with Tangier disease. The
presence of the G3805A mutation was detected by restriction
digestion with TspEI, which cuts the mutant allele only. Lanes:
M, molecular weight marker; 1, proband; 2, sister of the pro-
band; 3, normal control. (B) Sequence analysis of the ABCA1
cDNA region containing the C to T transition at nucleotide
6181. Sequences of a healthy control subject and a sister of the
proband (Fig. 1, II-3). The patient is homozygous for the muta-
tion. Arrow indicates the C to T transition at nucleotide 6181.
(Bottom) Restriction digestion polymorphism analysis of pa-
tients with Tangier disease. The presence of the C6181T muta-
tion was detected by restriction digestion with AgeI, which cuts
the mutant allele only. Lanes: M, molecular weight marker;
1, proband; 2, sister of the proband; 3, control subject.
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substitution of Arg 2021 with Trp in exon 47, and
mistakenly reported the substitution of Asp 1229
with Leu instead of Asn in exon 27. They showed
that apoA-I-mediated cholesterol e¥ux from the ¢-
broblasts of these subjects was 10% of that of control
subjects.
Mutations in the ABC1 gene have been also re-
ported in some patients with FHA [10,11]. In the
present study we checked three unrelated families
with FHA, and found the mutation in one family
with a 4 bp deletion, resulting in a premature stop
at codon 1224 by a frameshift (Fig. 4). Loo and
Clarke intensively investigated the biosynthesis of
P-glycoprotein which belongs to the ABC superfam-
ily of transport proteins. They found that changes in
49 of 401 arti¢cially mutagenized residues (12.2%) of
P-glycoprotein resulted in misprocessing [24]. Mis-
processing mutations are located throughout the
molecule; they include the transmembrane domains,
intracellular and extracellular loops, the linker re-
gion, and both nucleotide-binding domains [24]. In
this regard, the 4 bp deletion at nucleotides 3787^
3790 of the ABCA1 molecule might result in mispro-
cessing and degradation intracellularly and is prob-
ably non-functional. The truncation could occur
between the predicted seventh and eight trans-
membrane domains. Since skin biopsy was refused
by the family members, we could not determine
apoA-I-mediated cellular cholesterol e¥ux. The pro-
band had severe coronary heart disease but did not
show the typical TD phenotype, and he had no ton-
sillar abnormality, lymphadenopathy, hepatospleno-
megaly, or evidence of neuropathy. Mutations were
not detected in apoA-I and LCAT genes of the pro-
band.
The ABCA1 transporter plays a crucial role in the
apolipoprotein-mediated lipid removal pathway in
monocytes and ¢broblasts [15,22]. Both probands
of TD and FHA in our study developed coronary
Fig. 4. Diagram of the portion of the ABCA1 gene showing
the 4 nucleotide deletion, leading to a frameshift mutation and
premature termination in exon 27. The amino acid sequences of
a section of exon 27 from a normal subject and the FHA pro-
band are illustrated, and the underlined are the deleted nucleo-
tides. Numbers at the top of the sequence indicate the amino
acid residues of native ABCA1.
Fig. 3. Sequence analysis of the ABCA1 cDNA region in the patient with FHA containing the 4 bp deletion at nucleotides 3787^
3790. Sequences of a normal control subject and the proband are shown. The patient is homozygous for the mutation. Arrow indi-
cates the 4 bp deletion at nucleotides 3787^3790. (Bottom) Restriction digestion polymorphism analysis of the patient with FHA. The
presence of the 4 bp deletion at nucleotides 3787^3790 was detected by restriction digestion with NspV, which cuts the mutant allele
only. Lanes: M, molecular weight marker; 1, proband; 2, control subject.
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heart disease. This may imply the important role of
this pathway in intracellular cholesterol transport as
a key mechanism in atherogenesis. During the isola-
tion of monocytes, we observed that the number of
monocytes from the patient was clearly lower than
that of control subjects (unpublished observation),
implying that monocytes may be target cells in TD.
This is consistent with previously published data
[15,22]. However, in our case with TD, tonsillar en-
largement was not observed in either sibling [16].
Although mutations in ABCA1 are associated with
TD and FHA [3,11,12], the molecular mechanism
related to phenotypic heterogeneity of the disease
and FHA remains to be de¢ned.
In conclusion, we isolated RNA from monocyte-
derived macrophages from one of two previously de-
scribed Japanese patients with TD and FHA to gen-
erate ABCA1 cDNA by RT-PCR. We identi¢ed
three novel mutations at Asp 1229 with Asn substi-
tution in exon 27, Arg 2021 with Trp in exon 47 and
a 4 bp deletion at nucleotides 3787^3790 of the
cDNA in exon 27. The three mutations were not
found in 141 Japanese control subjects. Further stud-
ies are necessary to elucidate which of the two muta-
tions is mainly related to the phenotype of TD in our
case.
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